This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Prostate Disease  • Oncology  • Prostate Cancer  • Radiation Therapy  • Alert me on articles by topic

The New Standard?

Theodore L. DeWeese, MD

JAMA. 2004;292:864-866.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

One of every 6 men living in the United States will be diagnosed with prostate cancer at some point in his life.¹ Although the likelihood of death from such a diagnosis is much less than 1 in 6, nearly 30 000 men will die from prostate cancer this year.¹ Many men who die from this disease were originally diagnosed with clinically significant tumors, which were palpable, of an intermediate to high grade on review of the needle biopsy specimen, and/or associated with a serum prostate specific antigen (PSA) of more than 10 ng/mL.^2-3 The 10-year disease-free survival following surgical or nonsurgical therapy for such men is frequently less than 50%.⁴

Historically, locally advanced prostate cancer has been defined as a tumor that clearly extends outside the prostate as documented on digital rectal examination or imaging. Such patients are at high risk for disease recurrence following surgical or . . . [Full Text of this Article]

Author Affiliations: Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, Md.

RELATED ARTICLE

6-Month Androgen Suppression Plus Radiation Therapy vs Radiation Therapy Alone for Patients With Clinically Localized Prostate Cancer: A Randomized Controlled Trial
Anthony V. D'Amico, Judith Manola, Marian Loffredo, Andrew A. Renshaw, Alyssa DellaCroce, and Philip W. Kantoff
JAMA. 2004;292(7):821-827.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891
Studer et al.
JCO 2006;24:1868-1876.
ABSTRACT | FULL TEXT